Safety and immunogenicity of a respiratory syncytial virus prefusion F protein (RSVPreF3) candidate vaccine in older Japanese adults: A phase I, randomized, observer-blind clinical trial

Shady Kotb; Miwa Haranaka; Nicolas Folschweiller; Phoebe Nakanwagi; Céline Verheust; Nathalie De Schrevel; Marie-Pierre David; Narcisa Mesaros; Veronica Hulstrøm

doi:10.1016/j.resinv.2022.11.003

Safety and immunogenicity of a respiratory syncytial virus prefusion F protein (RSVPreF3) candidate vaccine in older Japanese adults: A phase I, randomized, observer-blind clinical trial

Respir Investig. 2023 Mar;61(2):261-269. doi: 10.1016/j.resinv.2022.11.003. Epub 2023 Jan 12.

Authors

Shady Kotb¹, Miwa Haranaka², Nicolas Folschweiller³, Phoebe Nakanwagi³, Céline Verheust³, Nathalie De Schrevel⁴, Marie-Pierre David³, Narcisa Mesaros³, Veronica Hulstrøm³

Affiliations

¹ GSK, Avenue Flemming 20, 1300 Wavre, Belgium. Electronic address: shady.x.kotb@gsk.com.
² SOUSEIKAI PS Clinic, Random Square 8th Fl, 6-18, Tenyamachi, Hakata-Ku, Fukuoka, Japan.
³ GSK, Avenue Flemming 20, 1300 Wavre, Belgium.
⁴ GSK, Rue de L'Institut 89, 1330 Rixensart, Belgium.

PMID: 36641341
DOI: 10.1016/j.resinv.2022.11.003

Abstract

Background: Respiratory syncytial virus (RSV) causes lower respiratory tract infection, with a high burden of disease among adults ≥60 years. This study assessed the safety, reactogenicity, and immunogenicity of an investigational adjuvanted RSV vaccine (RSVPreF3/AS01_B) in Japanese adults aged 60-80 years.

Methods: Forty participants were randomized to receive two doses of RSVPreF3/AS01_B or the placebo, in a 1:1 ratio, two months apart, in this placebo-controlled study. Solicited administration-site and systemic adverse events (AEs) were collected within 7 days and unsolicited AEs within 30 days post-vaccination. Serious AEs (SAEs) and potential immune-mediated diseases (pIMDs) were collected throughout the study (12 months post-dose 2). RSVPreF3-specific immunoglobulin G (IgG) antibody concentrations and neutralizing antibody (nAb) titers against RSV-A were evaluated on day (D)1, D31, D61, D91 and those against RSV-B on D1, D31, D91.

Results: Solicited AEs were reported more frequently in RSVPreF3/AS01_B recipients (80.0%-90.0%) than in placebo recipients (10.0%-20.0%). Two RSVPreF3/AS01_B recipients experienced grade 3 solicited AEs. Rate of unsolicited AEs were similar (30.0%-35.0%) in both groups. No RSVPreF3/AS01_B recipient reported SAEs/pIMDs, while one placebo recipient reported two SAEs that were unrelated to vaccination. Baseline RSVPreF3-specific IgG and RSV-A/-B nAb levels were above the assay cut-off values. In the RSVPreF3/AS01_B group, RSVPreF3-specific IgG concentrations increased 12.8-fold on D31 and 9.2-fold on D91 versus baseline while nAb titers increased 7.3-fold (RSV-A) and 8.4-fold (RSV-B) on D31 and 6.3-fold (RSV-A) and 9.9-fold (RSV-B) on D91.

Conclusions: The RSVPreF3/AS01_B vaccine was well tolerated and immunogenic in older Japanese adults.

Clinical trial registration number: NCT04090658.

Keywords: Immunogenicity; Older adults; RSV vaccine; Respiratory syncytial virus; Safety.

Publication types

Randomized Controlled Trial
Clinical Trial, Phase I

MeSH terms

Aged
Aged, 80 and over
Antibodies, Viral
East Asian People
Humans
Immunogenicity, Vaccine*
Immunoglobulin G
Middle Aged
Respiratory Syncytial Virus Infections* / prevention & control
Respiratory Syncytial Virus Vaccines* / immunology
Respiratory Syncytial Virus, Human

Substances

Antibodies, Viral
Immunoglobulin G
Respiratory Syncytial Virus Vaccines

Associated data

ClinicalTrials.gov/NCT04090658